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Abstract This randomized, double-blind study assessed
the antifracture efficacy and safety of intermittent intra-
venous (IV) ibandronate versus oral daily risedronate in
Japanese patients with primary osteoporosis. Ambulatory
patients aged C60 years were randomized to receive 0.5 or
1 mg/month IV ibandronate plus oral daily placebo or
2.5 mg/day oral risedronate, the licensed dose in Japan,
plus IV placebo. The primary end point was noninferiority
of ibandronate versus risedronate for first new or worsening
vertebral fracture over 3 years. A total of 1,265 patients
were randomized. A total of 1,134 patients formed the per-
protocol set. Both ibandronate doses were noninferior to
risedronate: 0.5 mg, hazard ratio (HR) 1.09 [95 % confi-
dence interval (CI) 0.77–1.54]; 1 mg, HR 0.88 (95 % CI
0.61–1.27). The rate of first new vertebral fracture over
3 years was 16.8 % (95 % CI 12.8–20.8) for 0.5 mg
ibandronate, 11.6 % (95 % CI 8.2–15.0) for 1 mg ibandr-
onate, and 13.2 % (95 % CI 9.6–16.9) for risedronate.
Significant increases in bone mineral density relative to
baseline were observed with all treatments after 6 months,
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with substantial reductions in bone turnover markers after
3 months. Greatest efficacy was obtained with 1 mg
ibandronate. Analyses in women only showed similar
results to the overall population. No new safety concerns
were identified. This study demonstrated the noninferiority
of IV ibandronate to the licensed Japanese dose of oral
risedronate and suggested that 1 mg/month is an effective
dose in Japanese patients with primary osteoporosis.
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The efficacy of ibandronate on vertebral fractures has been
demonstrated in postmenopausal osteoporosis [1, 2]. In the
randomized, double-blind trial BONE (oral iBandronate
Osteoporosis vertebral fracture trial in North America and
Europe), oral ibandronate 2.5 mg/day or 20 mg every other
day for 12 doses every 3 months significantly reduced the
risk of vertebral fracture and increased bone mineral den-
sity (BMD) at the lumbar spine and total hip versus placebo
[3]. Two further randomized studies, MOBILE (Monthly
Oral iBandronate In LadiEs) [2, 4–6] and DIVA (Dosing
IntraVenous Administration) [1, 7–9], confirmed the non-
inferiority of BMD gains in the lumbar spine with 100 and
150 mg once-monthly tablets or 2 mg/2 months or 3 mg/
3 months intravenous (IV) injections to those with daily
oral ibandronate 2.5 mg for up to 5 years. The efficacy of
ibandronate in increasing BMD in male osteoporosis
patients has also been reported [10].
Three large randomized studies have demonstrated the
efficacy of risedronate against vertebral, nonvertebral, and
hip fractures [11–13]. Compared with placebo, oral
risedronate 2.5 or 5 mg daily significantly reduced the
relative risk of hip fracture among elderly women with
confirmed osteoporosis in the HIP (Hip Intervention Pro-
gram) study, with relative risks of hip fracture of 0.5 and
0.7, respectively [11]. Oral risedronate (2.5 or 5 mg daily)
also significantly reduced the risk of new vertebral fracture
by 46 and 65 %, respectively, compared with placebo in
the VERT-NA (Vertebral Efficacy with Risedronate
Therapy North America) study, and reduced the fracture
risk by similar amounts in postmenopausal women with
prevalent vertebral fractures in the VERT-MN (VERT-
Multinational) study [14]. The plasma concentrations of
risedronate attained while on treatment with 2.5 mg oral
risedronate in Japanese subjects were almost comparable
with those of 5 mg dosing in white subjects [15]. Fur-
thermore, BMD increases at the lumbar spine and changes
in bone turnover markers (BTMs) were comparable in
Japanese subjects who received 2.5 mg/day risedronate and
in white patients who received 5 mg/day risedronate [13,
16]. In a dose-ranging study of risedronate in Japanese
patients with osteoporosis, a linear dose–response rela-
tionship for increases in BMD and decreases in BTMs was
obtained up to a dose of 2.5 mg, but no further increase
was observed with 5 mg risedronate [17]. Based on these
results, the optimal oral dose of risedronate in Japanese
osteoporotic patients was determined and licensed as
2.5 mg daily or 17.5 mg weekly [18]. Reduction in fracture
risk has been observed for vertebral [19] and hip [20]
fractures at this dose. Although placebo-controlled data for
fracture risk have not been obtained in Japanese patients,
risedronate 2.5 mg daily is a suitable active comparator to
assess fracture prevention efficacy in Japanese osteoporotic
patients.
European and North American patients enrolled in
BONE achieved comparable efficacy with ibandronate
[21], but the effect on osteoporosis fracture risk has not
been well investigated in nonwhite patients. In a random-
ized study in Japanese women with postmenopausal oste-
oporosis, IV ibandronate 0.5 mg/month, 1 mg/month and
2 mg/2 months substantially increased lumbar spine BMD
and significantly reduced BTMs compared with placebo
[22]. Meta-analyses have shown that fracture risks of men
and women are similar for any given BMD [23, 24]; thus
postmenopausal osteoporosis and osteoporosis in elderly
men can be categorized as primary osteoporosis with
possible heterogeneous pathogenesis [25, 26]. The current
study was conducted for registration purposes in Japan and
evaluated the efficacy and safety of IV ibandronate 0.5 mg
and 1 mg/month versus oral daily risedronate 2.5 mg (the
licensed dose in Japan) in terms of vertebral fracture
incidence in patients with osteoporosis, including both
postmenopausal women and older men.
Materials and Methods
Study Design
The MOVER (MOnthly intraVenous ibandronatE versus
daily oral Risedronate) study was a prospective, random-
ized, double-blind, active drug-controlled study comparing
IV ibandronate (0.5 mg and 1 mg/month) with 2.5 mg/day
oral risedronate over 3 years in women and men (Clini-
calTrials.gov identifier: NCT00447915). The primary end
point was noninferiority of ibandronate versus risedronate
with regards to the incidence of nontraumatic morpho-
metric vertebral fractures at 3 years. Institutional review
boards from the participating centers provided ethical
approval and the study was conducted in accordance with
the Declaration of Helsinki and the International Confer-
ence on Harmonization of Good Clinical Practice Guide-
lines. All patients provided written informed consent prior
to any study-related procedure.
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Patients
Ambulatory women or men aged C60 years with primary
osteoporosis according to the Diagnosis Criteria of Primary
Osteoporosis in Japan [27] were eligible if they had: fragile
bone fracture (nontraumatic osteoporotic fracture that
occurred by slight external force combined with low
BMD); BMD of the lumbar spine (L2–L4), or proximal
femur (total hip and femoral neck) \80 % of the young
adult mean (equivalent to T score–1.7,–1.6, and–1.4,
respectively); and 1–5 radiographically confirmed vertebral
fractures in the fourth thoracic spine–fourth lumbar spine
(Th4–L4).
Exclusion criteria included: vertebral deformations likely
to affect vertebral strength; previous radiotherapy of the tho-
racic spine/lumbar spine/pelvis; secondary osteoporosis or a
disease causing decrease in bone volume; a disorder delaying
the passage of food through the esophagus; received/planned
invasive dental procedures; bisphosphonate use within 1 year
of the start of the study, or prior treatment with ibandronate,
anti-RANKL antibody (AMG162) or strontium; receipt of
drugs likely to affect bone metabolism within 8 weeks of the
start of the study; severe cardiac, renal or hepatic disease;
calcium outside the criteria value (i.e., \8.4 mg/dL or [
10.4 mg/dL); hypersensitivity to bisphosphonate, calcium or
vitamin D; active malignant tumor or prior therapy for
malignant tumor within 3 years.
Treatment
Patients were randomly assigned to receive: 0.5 mg/month
IV ibandronate (F. Hoffmann-La Roche, Ltd.) plus oral
daily placebo for 36 months; 1 mg/month IV ibandronate
plus oral daily placebo; or 2.5 mg/day oral risedronate
(Ajinomoto Co. Inc.) plus IV placebo by the double dummy
method. All patients received supplementary calcium
305 mg and vitamin D 200 IU/day [28] as a single tablet
daily throughout the study period. IV study drug adminis-
tration was recorded by the investigator at the time of
dosing, while oral study drug administration was surveyed
by the patient and recorded by the investigator. Based on
published data comparing the efficacy and safety of 1 and
2 mg/2 months IV ibandronate in Japanese patients [22],
the 1 mg/month dose was selected for the current study. As
weekly risedronate was not marketed in Japan when the
study was planned, and daily risedronate was the most
popular bisphosphonate in use, daily oral risedronate was
selected as the active comparator for this trial.
Randomization and Blinding
Randomization was performed centrally through dynamic
allocation (minimization method) based on the number of
prevalent vertebral fractures (1 vs. [1). Patients, investi-
gators, steering committee members, the sponsor, and the
faculty who adjudicated the study end points remained
unaware of treatment-group assignments throughout the
trial.
Study End Points
The primary end point was the incidence of nontraumatic
morphometric vertebral fractures including new vertebral
fractures and worsening of prevalent vertebral fractures at
3 years. Secondary end points were: the incidences of
nontraumatic new vertebral fractures, all osteoporotic
nonvertebral fractures, osteoporotic nonvertebral fractures
at the six major sites (femur, forearm, humerus, clavicle,
tibia/fibula, pelvis), clinical vertebral fractures, and total
clinical fractures; percentage change from baseline in
lumbar spine (L2–L4), total hip, trochanter and femoral
neck BMD; change from baseline in BTMs of urinary C-
and N-telopeptide of type 1 collagen corrected by creati-
nine (uCTX and uNTX, respectively), serum bone-specific
alkaline phosphatase (BALP) and osteocalcin (OC); and
safety.
Schedule of Assessments
Radiographs of the thoracic and lumbar spine were taken at
screening, baseline, and at 6, 12, 24, and 36 months after
treatment for the assessment of fractures. To identify
morphometric vertebral fractures, the vertebral bodies of
the lateral projection from Th4 to L4 were assessed using
semiquantitative (SQ) methodology and quantitative mor-
phometry (QM) [29] by a central committee who were
blinded to treatment. Prevalent fractures were defined as
vertebrae with an anterior/posterior height ratio \0.75, or
central/posterior height ratio\0.80, or a 20 % reduction in
any of the anterior, posterior, or central vertebral heights
from corresponding values in the adjacent upper or lower
vertebra. A new vertebral fracture was defined as an
increase of C1 SQ grading scale in a vertebra that was
normal at baseline, while a worsening fracture was defined
as an increase of C1 SQ grading scale in a vertebra that
was deformed at baseline. Fracture incidence was adjudi-
cated by three experts with reference to QM data from
Synarc (San Francisco) and a binary SQ assessment was
made. Radiographs were assessed to identify nonvertebral
fractures in patients with clinical symptoms.
BMD measurements in lumbar spine (L2–L4), total hip,
trochanter and femoral neck were performed centrally at
screening, baseline, 6, 12, 24, and 36 months using dual-
energy X-ray absorptiometry of Hologic and Lunar bone
densitometers. BTMs were measured centrally at baseline,
3, 6, 12, 24, and 36 months. Urine samples were obtained
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under fasting conditions. All samples were collected prior
to administration of injection.
Adverse events (AEs) were summarized throughout the
study and for up to 15 days after study end. AEs of interest
such as renal, cardiac and gastrointestinal functions, acute
phase reactions (APRs), hypocalcemia, osteonecrosis of the
jaw, and atypical fracture of the femur, were specified in
advance.
Statistical Analyses
The primary analysis was performed on the per-protocol
set (PPS). For the analysis of vertebral fracture incidence,
stratified Cox regression with number of prevalent verte-
bral fractures (1 vs. C2) and age (60–74 vs. C75 years) as
stratified variables and life table method was used. The log
rank test was applied for between-treatment group com-
parisons of fracture incidence. To control the overall sig-
nificance level, a closed testing procedure from higher dose
was applied. Noninferiority of IV ibandronate to oral
risedronate would be concluded if the upper limit of the
90 % confidence interval (CI) of the hazard ratio (HR) was
below the confidence limit of noninferiority of 1.55.
Analyses of BMD and BTMs were based on the relative
change from baseline and between-treatment group com-
parisons were performed by t test. Missing data were
imputed by the last observation carried forward method.
Based on published data [19], the fracture incidence rate
of risedronate after 3 years was estimated to be 17 % and
that of ibandronate to be 16 %. Under these assumptions,
we calculated that 295 patients were required in each
treatment group to assess the noninferiority of ibandronate
to risedronate with the HR threshold value of 1.55. A one-
sided significance level of 0.05 was set, with a detection
power of 80 % by the Shoenfeld method. With an expected
drop-out rate of 25 %, 394 patients were required in each
treatment group, giving a total of 1,182 patients. The study
was not designed to compare the two ibandronate doses;
however, their significance was assessed as an exploratory
measure.
Results
Patient Disposition and Baseline Characteristics
A total of 1,265 patients were randomized. Thirty-seven
patients did not receive study treatment, leaving 1,228
patients in the safety population: 411, 411 and 406 patients
(389, 381 and 371 women) were randomized to receive
ibandronate 0.5 mg, ibandronate 1 mg, and risedronate,
respectively (Fig. 1). Overall, 909 patients (854 women)
completed the study. The PPS for the primary end point
analysis comprised 1,134 patients, including 376, 382 and
376 (356, 354 and 343 women) in the ibandronate 0.5 mg,
ibandronate 1 mg and risedronate groups, respectively
(Table 1). Baseline patient characteristics were well bal-
anced between the treatment groups.
The modified intent-to-treat (ITT) population of 1,220
patients included 404, 411 and 405 patients (382, 381 and
370 women) in the ibandronate 0.5 mg, ibandronate 1 mg,
and risedronate groups, respectively. No difference in
discontinuation rate was found between the groups: 25.8,






Fig. 1 Patient flow through the
study (men and women)
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modified ITT population were[96 % for IV administration
and [93 % for oral administration.
Mean 25-hydroxyvitamin D levels were low at baseline
(Table 1), but increased above 25.0 ng/mL in all treatment
groups after 3 years: 26.6 ng/mL [standard deviation (SD)
6.09], 26.6 ng/mL (SD 6.71), and 26.9 ng/mL (SD 6.07) in
the ibandronate 0.5 mg, ibandronate 1 mg and risedronate
groups, respectively.
Incidence of Vertebral Fractures
There was no difference in the incidence of morphometric
vertebral fractures at screening or at baseline. The cumu-
lative incidences of new or worsening vertebral fractures
over 3 years were 19.9 % (95 % CI 15.6–24.1), 16.1 %
(95 % CI 12.2–19.9) and 17.6 % (95 % CI 13.6–21.6) for
the ibandronate 0.5 mg, ibandronate 1 mg, and risedronate
groups, respectively. Compared with the risedronate group,
the HRs for fracture incidences were 1.09 (95 % CI
0.77–1.54) and 0.88 (95 % CI 0.61–1.27) for ibandronate
0.5 mg and 1 mg, respectively (Fig. 2a). The HRs for
fracture incidences for women only were 1.08 (95 % CI
0.75–1.55) and 0.95 (95 % CI 0.66–1.39), respectively,
over 3 years (Fig. 2b). At 2 years, the incidence of verte-
bral fractures in women only was 13.4 % (95 % CI
9.8–17.1), 11.0 % (95 % CI 7.6–14.3) and 12.8 % (95 %
CI 9.1–16.4) for the ibandronate 0.5 mg, ibandronate 1 mg,
and risedronate groups, respectively, with HRs of 1.01
(95 % CI 0.66–1.54) and 0.83 (95 % CI 0.53–1.29),
respectively. At 1 year, the fracture incidence in women
only was 9.6 % (95 % CI 6.5–12.7), 8.4 % (95 % CI
5.5–11.4) and 10.8 % (95 % CI 7.4–14.1), with respective
HRs of 0.85 (95 % CI 0.53–1.37) and 0.76 (95 % CI
0.46–1.23).
The cumulative incidences of first new vertebral frac-
tures were 16.8 % (95 % CI 12.8–20.8), 11.6 % (95 % CI
8.2–15.0), and 13.2 % (95 % CI 9.6–16.9) for the ibandr-
onate 0.5 mg, ibandronate 1 mg, and risedronate groups,
respectively (Fig. 2c). The HR for the ibandronate groups
compared with the risedronate group were 1.27 (95 % CI
0.86–1.89) and 0.87 (95 % CI 0.57–1.33) for the 0.5 mg
and 1 mg doses, respectively; the difference between the






(n = 376) (n = 382) (n = 376)
Women, n (%) 356 (94.7) 354 (92.7) 343 (91.2)
Age (year), mean (SD) 72.9 (6.34) 72.2 (6.38) 73.0 (6.29)
Aged 60–74 year, n (%) 219 (58.2) 245 (64.1) 227 (60.4)
Aged C75 year, n (%) 157 (41.8) 137 (35.9) 149 (39.6)
Weight (kg), mean (SD) 50.6 (8.00) 50.9 (7.36) 51.1 (8.35)
Height (cm), mean (SD) 149.2 (6.66) 149.5 (6.56) 149.4 (6.70)
BMD T-score, mean (SD)
Lumbar spine (L2–L4) -2.71 (1.01) -2.68 (1.01) -2.59 (1.06)
Femoral neck -2.48 (0.73) -2.41 (0.80) -2.53 (0.79)
Total hip -2.17 (0.87) -2.09 (0.86) -2.18 (0.86)
Prevalent vertebral fractures, n (%)
1 186 (49.5) 184 (48.2) 183 (48.7)
2 97 (25.8) 106 (27.7) 95 (25.3)
[2 93 (24.7) 92 (24.1) 98 (26.1)
uCTX (lg/mmol CR),
mean (SD)
382.4 (226.2) 368.6 (209.9) 373.2 (261.0)
uNTX (nM BCE/mM
CR), mean (SD)
73.6 (39.31) 69.4 (35.42) 68.9 (35.16)
BALP (IU/L), mean
(SD)
33.6 (13.15) 33.9 (13.11) 32.4 (11.96)
25-OH vitamin D (ng/
mL), mean (SD)
19.6 (6.44) 20.0 (6.69) 19.7 (6.56)
BALP bone-specific alkaline phosphatase, BCE bovine collagen equivalent,
BMD bone mineral density, CR creatinine, SD standard deviation, uCTX
creatinine-corrected urinary collagen type 1 cross-linked C-telopeptide, uNTX












































Ibandronate 1 mg (n = 382)
Ibandronate 0.5 mg (n = 376)
Risedronate (n = 376)
Fig. 2 Vertebral fracture efficacy: forest plot of hazard ratios for the
first new or worsening vertebral fracture in a all patients and b women
only. c Life table analysis for the first new vertebral fractures during
the study. CI confidence interval
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0.5 mg and 1 mg ibandronate doses was not statistically
significant (P = 0.062).
Incidence of Osteoporotic Nonvertebral Fractures
and Clinical Fractures
The cumulative incidences of osteoporotic nonvertebral
fractures were 9.0, 7.2, and 8.4 % for the ibandronate
0.5 mg, ibandronate 1 mg, and risedronate groups,
respectively (Fig. 3). The difference between the ibandro-
nate groups was not statistically significant. The respective
values for the major six nonvertebral fractures were 5.3,
4.6, and 6.3 %. Differences between the treatment groups
were not statistically significant for any of the fracture end
points.
Bone Mineral Density
At 3 years, the mean relative change from baseline in BMD
values for the ibandronate 0.5, 1 mg and risedronate groups
was 7.7, 9.0, and 7.6 %, respectively, for the lumbar spine
(Fig. 4a), and 2.2, 3.1, and 2.0 %, respectively, for the total
hip (Fig. 4b). Respective values at the trochanter were 3.8,
4.7, and 3.1 %, and at the femoral neck were 2.1, 3.1, and
2.2 %. Significant differences were noted in lumbar spine
BMD between the 1 mg and 0.5 mg ibandronate dose
groups at 1 year (P = 0.030), 2 years (P = 0.001), and
3 years (P = 0.010), and in total hip BMD at 2 years
(P = 0.029) and 3 years (P = 0.006). Intergroup differ-
ences in BMD between the ibandronate groups were not
significant at the trochanter. BMD changes in women
showed similar trends in all three treatment groups (data
not shown).
Bone Turnover Markers
The mean relative change from baseline in uCTX (Fig. 4c)
and uNTX levels was similar with ibandronate 1 mg and
risedronate, with an initial decrease at 3 months and levels
maintained below baseline throughout the study. Mean
reductions from baseline at 6 months with 1 mg ibandro-
nate were 67 and 53 % for uCTX and uNTX, respectively.
With ibandronate 0.5 mg, decreases in uCTX and uNTX
were less than those in the other treatment groups, and
there was no overlap between the 95 % CIs with either
ibandronate 1 mg or risedronate.
In the ibandronate 1 mg group, serum BALP (Fig. 4d)
and OC levels decreased at 3 months and remained below
baseline thereafter; at 6 months, mean relative changes
from baseline were 41 and 35 %, respectively. Decreases
in serum BALP and OC levels in the ibandronate 0.5 mg
and risedronate groups were less than those in the ibandr-
onate 1 mg group and the 95 % CIs of the ibandronate
0.5 mg and risedronate groups did not overlap with those
of the ibandronate 1 mg group. Significant differences
were noted between the ibandronate groups at each time
point for all BTMs (P \ 0.005). Women showed similar
changes as the overall population (data not shown).
Adverse Events
No significant differences were observed between the
treatment groups with respect to the incidence of all AEs,
serious AEs, AEs leading to death or AEs leading to
withdrawal (Table 2). Regarding AEs of interest, the most
frequently reported renal-related AEs were increased blood
creatinine and the presence of protein in urine. All renal
function-related AEs were mild, and there were no sig-
nificant differences in incidence between the groups
(Table 3). Most APR AEs were mild in intensity and
transient, and decreased with each subsequent dose of
medication (Fig. 5). No AE leading to treatment discon-
tinuation by APR was reported.
Discussion
We compared the efficacy and safety of IV ibandronate
0.5 mg and 1 mg/month with that of oral risedronate
2.5 mg daily (the licensed dose in Japan), in terms of
fracture, BMD, and BTMs in postmenopausal women and
older men with osteoporosis for registration purposes in
Japan. Both doses of ibandronate were noninferior to
Fractures
Fig. 3 Incidences of osteoporotic nonvertebral fractures, major six
nonvertebral fractures, first clinical vertebral fractures, and total
clinical fractures through 3 years. P value (log rank) for ibandronate
versus risedronate: *P = 0.652 (0.5 mg), P = 0.605 (1 mg) P =
0.752 (0.5 mg), P = 0.449 (1 mg) P = 0.468 (0.5 mg), P = 0.568
(1 mg) §P = 0.497 (0.5 mg), P = 0.298 (1 mg)
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risedronate with respect to the risk of vertebral fracture. As
this active control study represents the first head-to-head
comparison of the antifracture efficacy of two nitrogen-
containing bisphosphonates, we closely mirrored the
enrollment criteria and design of the registration trial of
risedronate in Japanese patients with osteoporosis [19].
Indeed, the fracture rates observed with risedronate in our
study compared well with those of the Japanese registration
trial [19]. Significant increases in BMD from baseline were
observed in all treatment groups, with ibandronate 1 mg
demonstrating the greatest overall gains. Rapid decreases
in BTMs were seen and were consistent with the BMD
results. The safety profile of these agents was generally
similar, and all regimens were well tolerated.
Over 3 years, the incidence of new or worsening ver-
tebral fractures, and just new vertebral fractures, did not
differ significantly between the ibandronate 0.5 and 1 mg
groups, although fracture incidence was numerically higher
with the 0.5 mg dose. The same findings were observed
between the ibandronate 1 mg and risedronate groups, with
a higher numerical incidence of fractures in the risedronate
group. Both doses of ibandronate met the noninferiority
criteria compared with risedronate. However, the HR for
fracture incidence for 1 mg ibandronate versus risedronate
was in fact smaller than for 0.5 mg ibandronate versus






(n = 411) (n = 411) (n = 406)
Any AE 406 (98.8 %) 401 (97.6 %) 393 (96.8 %)
Serious AEs 101 (24.6 %) 102 (24.8 %) 132 (32.5 %)
AEs leading to death 5 (1.2 %) 3 (0.7 %) 6 (1.5 %)
AEs leading to
withdrawal
34 (8.3 %) 42 (10.2 %) 38 (9.4 %)
Serious AEs leading
to withdrawal
27 (6.6 %) 28 (6.8 %) 27 (6.7 %)
Most common AEs
Nasopharyngitis 188 (45.7 %) 209 (50.9 %) 201 (49.5 %)
Contusion 99 (24.1 %) 89 (21.7 %) 99 (24.4 %)
Osteoarthritis 75 (18.2 %) 63 (15.3 %) 51 (12.6 %)
Back pain 53 (12.9 %) 80 (19.5 %) 55 (13.5 %)
Arthralgia 54 (13.1 %) 47 (11.4 %) 38 (9.4 %)
Constipation 43 (10.5 %) 43 (10.5 %) 55 (13.5 %)
Diarrhea 23 (5.6 %) 15 (3.6 %) 19 (4.7 %)
Bronchitis 12 (2.9 %) 18 (4.4 %) 17 (4.2 %)
Urinary tract
infection
9 (2.2 %) 4 (1.0 %) 10 (2.5 %)




Day 1 Day 1
Day 1 Day 1
u
n nn
Fig. 4 Mean relative change from baseline (with 95 % CI) through-
out 3 years in a BMD at the lumbar spine (L2–L4); b BMD at the
total hip; c uCTX; d serum BALP. P value (t test) for 1 mg
ibandronate versus risedronate: L2–L4: P = 0.001 (6 months), P =
0.001 (24 months), P = 0.005 (36 months), total hip: P = 0.001
(24 months), P \ 0.001 (36 months), *P \ 0.005 for 1 mg ibandro-
nate versus 0.5 mg ibandronate. CI confidence interval, L lumbar,
BMD bone mineral density, uCTX creatinine-corrected urinary
collagen type 1 cross-linked C-telopeptide, BALP bone-specific
alkaline phosphatase
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risedronate. Thus, the superiority of ibandronate over
risedronate in increasing BMD may account for a small
differential in fracture risk reduction [30]. Dose depen-
dency of ibandronate on the incidence of vertebral fractures
was shown numerically, but was not statistically signifi-
cant. The efficacy of ibandronate in women only at 2 and
3 years was consistent.
We observed a similar rate of nonvertebral fractures
between the ibandronate groups and the risedronate group,
with the 1 mg ibandronate group having the lowest
numerical incidence. The efficacy of 1 mg ibandronate was
consistently greater than the 0.5 mg dose but this was not
statistically significant. The 1 mg ibandronate group
showed a nonsignificant improvement with a 27 % relative
risk reduction in the incidence of the major six nonvertebral
fractures versus risedronate. The VERT studies previously
highlighted the nonvertebral fracture efficacy of risedronate
in a white population [12, 13]. Additionally, a 3-year study
in Japanese patients with osteoporosis who had previously
undergone surgery for hip fracture, reported that risedronate
2.5 mg significantly reduced the incidence of contralateral
hip fracture [20]. In the present study, the risk ratio of
nonvertebral fracture between the 1 mg [annual cumulative
exposure (ACE) 12 mg] and 0.5 mg (ACE 6 mg) ibandro-
nate groups was 0.80 (95 % CI 0.47–1.36), which is within
the range described in a pooled analysis of different
ibandronate doses [31]. Our study therefore provides sup-
portive data for the dose dependency of ibandronate on the
risk of nonvertebral fractures in patients with osteoporosis.
BMD gains at all sites were substantial and significantly
improved over baseline in all treatment groups. Treatment
with IV ibandronate 1 mg/month in the current study
resulted in similar BMD gains as obtained with IV
ibandronate 2 mg/2 months and 3 mg quarterly in white
women [1]. The effects of IV ibandronate on BMD gains
appear to be dose-dependent and similar between Japanese
and white patients. Changes in BTMs were comparable
with those in previous studies and did not increase the risk
of skeletal complications such as atypical femoral fractures
over 3 years. Median changes from baseline in serum
BALP in the risedronate 2.5 mg group were equivalent to
changes observed with risedronate 5 mg in white patients
[12, 13]. Compared with the 0.5 mg dose, treatment with
IV ibandronate 1 mg/month resulted in significantly greater
decreases in all BTMs. These data are compatible with the
dose-dependent reductions in uCTX and serum OC repor-
ted with IV ibandronate 0.5 mg and 1 mg every 3 months
[32]. Although the inhibition profile over time may differ
between the dosing intervals of 1 and 3 months, the dose
dependency on BTMs of IV ibandronate appears to be
maintained. We noted similar reductions in uCTX and
uNTX between the 1 mg ibandronate and risedronate
groups in the present study, but reductions in serum BALP
and OC differed between these groups, with greatest effi-
cacy shown for 1 mg ibandronate [33]. Of note, the col-
lection of urine and serum samples for BTM analysis was
performed prior to monthly drug administration, at which
point values were returning to baseline and the true effects
of the time-course of treatment could not be seen.
The safety profile in this Japanese population was sim-
ilar to previous studies in Western patients with no
apparent increase in the nature and/or severity of AEs. APR
was commonly experienced following the first adminis-
tration of IV bisphosphonates. The range of symptoms that
included specific (e.g., myalgia) and nonspecific (e.g., back
pain, headache) AE terms were evaluated by onset and
duration. The incidence of these symptoms was higher with













Ibandronate 0.5 mg (n = 411)
Ibandronate 1 mg (n = 411)
Risedronate (n = 406)
Time (months)
0 1 2 3 4 5
Fig. 5 Change in the incidence of acute phase reactions between first
and subsequent dose of study medication






(n = 411) (n = 411) (n = 406)
Renal function
related
12 (2.9 %) 11 (2.7 %) 8 (2.0 %)
GI related 113 (27.5 %) 120 (29.2 %) 108 (26.6 %)
Serious GI related 5 (1.2 %) 2 (0.5 %) 9 (2.2 %)
Cardiac related 7 (1.7 %) 5 (1.2 %) 4 (1.0 %)
APR related 37 (9.0 %) 46 (11.2 %) 20 (4.9 %)







AE adverse event, GI gastrointestinal, APR acute phase reaction
a As per the American Society of Bone and Mineral Research case
definition
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to the different administration routes, but they were
reported at a similar frequency to previous studies [1, 9].
Symptoms defined as APR were mild to moderate in
intensity, transient and associated with the first adminis-
tration, as reported in earlier trials of ibandronate in oste-
oporosis [1, 4]. No difference in gastrointestinal, cardiac or
renal AEs was noted among the treatment groups, possibly
due to the double dummy design. Thus, 0.5 mg or 1 mg/
month IV ibandronate appears to be well tolerated
by Japanese osteoporotic patients with a similar safety
profile to the established quarterly regimen in the Western
population.
The study is limited by the lack of a placebo group due
to ethical reasons for the 3-year treatment period in high-
risk patients. In addition, the daily dose of supplemental
vitamin D was low compared with recent studies in Wes-
tern populations. Furthermore, differences in inclusion
criteria existed in this study and the BONE and DIVA
studies, such that the incidence rates of fracture and BMD
values are not directly comparable.
In summary, monthly IV ibandronate demonstrated
noninferiority to daily oral risedronate (at the dose licensed
in Japan) in reducing the incidence of vertebral fractures in
Japanese patients with primary osteoporosis. The safety
profile of the 0.5 mg and 1 mg ibandronate doses and the
2.5 mg risedronate was comparable. These data suggest
that 0.5 or 1 mg IV ibandronate is an effective option for
the treatment of primary osteoporosis in Japanese patients,
and that the 1 mg dose could be more beneficial in this
patient group.
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